Biohaven Ltd. (BHVN) Q3 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Quarter 2021 earnings call. Speaking on today's call from Biohaven are Dr. Vlad Chorich, our Chief Executive Officer, Jim Englehart, Chief Financial Officer, BJ Jones, Chief Commercial Officer, and Dr. Elise Stock, Chief Medical Officer. We also welcome Nick Ligonowitz, Global President, Pfizer Internal Medicine. Earlier this morning, we issued a press release announcing the third quarter 2021 highlights. A copy of this press release can be found on our website at biowaveandpharma.com, and we will file our Form 10-Q later today. Before we begin, let me remind everyone that today's discussion contains forward-looking statements based on the environment as we currently see it, and includes risks and uncertainties. A list and description of risks and uncertainties associated with an investment in Biohaven can be found in the company's filings with the U.S. Securities and Exchange Commission. Please be aware that you should not place undue reliance on any forward-looking statements we make today. For this call, we will focus on non-GAAP financial measures. Detailed descriptions of these non-GAAP measures and reconciliations to the most comparable GAAP measures can be found in our SEC filings. An archive of today's call will be posted to Biohaven's website in the investor relations section. With that, I will turn the call over to our CEO, Dr. Vlad Shorch. Thank you, Caroline, and good morning. And thank you to our investors for joining the third quarter earnings call. This has been another exceptional quarter for Biohaven. Not only has NERTEC ODT become the number one migraine treatment in its class, allowing patients and doctors to customize a single migraine therapy to treat and prevent attacks, but we are also excited to announce an outstanding strategic commercializat...